Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06233331Phase 1Not Yet Recruiting

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

Role: collaborator

NCT00209092Phase 2Completed

Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer

Role: collaborator

NCT00415285Phase 2Unknown

Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer

Role: lead

All 3 trials loaded